MRK 1
Alternative Names: CCR5 antagonists - Merck; Merck compound ALatest Information Update: 30 Mar 2010
At a glance
- Originator Merck & Co
- Class Amino acids; Antiretrovirals; Pyrazoles
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections; Transplant rejection
Most Recent Events
- 10 Sep 2004 Discontinued - Preclinical for HIV-1 infections in USA (unspecified route)
- 10 Sep 2004 Preclinical trials in Transplant rejection in USA (unspecified route)
- 10 Sep 2004 Data presented at the 228th American Chemical Society National Meeting - (228th-ACS-2004) have been added to the Transplant Rejection pharmacodynamics section